Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
The company has been working with PYC for about 15 years. Very capable bunch. However, the data always needs to go through committee including the company, as a sponsor, with a leading, nominated person, well qualified medical third party monitor person, resgulator, hospital etichs committee, principal investigator etc. When you have done all that then you have a chance of being on the top of the data, which is generated during several years. On the whole, the committee has a conf call about once a week a so, and they tend to question (person) involved in clinical trials very hard.
The work of 201 was conducted by late chairman Oliver, George and Victoria (now elsewhere since about a year) together with UCLH under MHRA. The data, which was gathered before C19 outbrake is of course still there with UCLH and available. Most of it was RNSd well back then. And also summarised as update.
I don’t know who you refer as G&M. But perhaps you should realise that ValiRx supported Suzy, Valiseek and 401 project several years. Financially, scientifically and psychologically in a great way. So perhaps you should think before making such comments.
You may have realised that the individuals who you are ****ging off have managed to take cancer drug from lab through first stage of clinical trials - successfully. And got worldwide patents granted. Meanwhile, helped the cancer patients. I don’t think that is a trivial task, but if you have done that better at some point, salute.
I think you may have meant robbing, not robing, which may have a bit different meaning. And I never discuss other people on social media, be friend or not. Just one comment. There was one intelligent individual lately, who rightly pointed out that people who cannot read or write and are stupid, don’t usually achieve doctorate from major London university. That, in my mind was very well said.
I don’t know who is firing insults, but sure not previous directors. It is not their style and if I were them, I would find it insulting that some individuals even suggest this. I’m looking forward for any potential peer reviewed studies of 201 antiviral function. These studies take a while and have to be conducted well and then verified by well qualified third parties. This can be expensive exercise, of course AZ et al can afford this. We all hope that there will be help for C19 soon, I’m just recovering from this infection, cannot recommend for anyone. It is very civilised to stop name calling et al and concentrate on future.
No, I’m not making anything up. George, the sponsor of clinical trials, resigned, Victoria, the main qualified Medical person, resigned and Tarquin, the investor relations person resigned. And you decided to vote as you did. Of course, Oliver who unfortunately passed away, would have never allowed this.
Now there are no individuals who were part of initial and ongoing ValiRx clinical trials and patent filings.
Yes, after being able to go through successful clinical trials and worldwide patent approvals, I was, as you put it, “booted out”. I’m not saying what several industry experts think about it, but good luck with your investments.
S